Sync-T-sv-102 early results 85% ORR

Very good results, 5 CR out of 13.

biospace.com/article/releas...

[NickJoy]

Thank you for posting this.

[KocoPr]

more good news!

[Soumen79]

Thank you for posting this -

The Phase 1 trial enrolled 15 mCRPC subjects, most of whom had diffuse bone metastases and had experienced failure with prior therapies. Subjects received SYNC-T therapy with the SV-102 multi-target biologic drug every four weeks for up to 12 cycles with response evaluation every eight weeks. SYNC-T demonstrated an ORR of 85% with five complete responses (CRs) and six partial responses (PRs) among the 13 evaluable subjects. The treatment was well tolerated, with minimal side effects and no significant safety concerns. The trial is ongoing, with results expected in the second half of 2024.

[NPfisherman]

Oslo,

Thanks for posting this information...

Incredible results... for those with bony metastasis, this could really make a difference in survival... Of course, it will be 10 years or more going through our "system" versus 3 years in China.... but still....great news...

All the best,

DD

[Scout4answers]

Great find.